Journal ArticleDOI
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich,Volker Diehl,Helen Görgen,Thomas Pabst,Jana Markova,Jürgen Debus,Anthony D. Ho,Bernd Dörken,Andreas Rank,Anca-Ligia Grosu,Thomas Wiegel,Johann H. Karstens,Richard Greil,Normann Willich,Heinz Schmidberger,Hartmut Döhner,Peter Borchmann,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Andreas Engert +19 more
Reads0
Chats0
TLDR
Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL, and four cycles of ABVD should be followed by 30 Gy of IFRT.Abstract:
Purpose Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied. Patients and Methods Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 × 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPbaseline) + 30 Gy of IFRT; or four cycles of BEACOPPbaseline + 20 Gy of IFRT. Results With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free...read more
Citations
More filters
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford,Timothy M Illidge,Nicholas Counsell,Barry W. Hancock,R. Pettengell,Peter Johnson,Jennie Z Wimperis,Dominic Culligan,Bilyana Popova,Paul Smith,Andrew McMillan,Alison Brownell,Anton Kruger,Andrew Lister,Peter Hoskin,Michael O'Doherty,Sally F. Barrington +16 more
TL;DR: Patients with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy, and the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival did not show.
Journal ArticleDOI
Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Lena Specht,Joachim Yahalom,Timothy M Illidge,Anne Kiil Berthelsen,Louis S. Constine,Hans Theodor Eich,Theodore Girinsky,Richard T. Hoppe,Peter Mauch,N. George Mikhaeel,Andrea K. Ng +10 more
TL;DR: A new concept, involved site radiation therapy (ISRT), is introduced as the standard conformal therapy for the scenario, commonly encountered, wherein optimal imaging is not available, and it is more conservative than INRT, accounting for suboptimal information and appropriately designed for safe local disease control.
Journal ArticleDOI
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dennis A. Eichenauer,Andreas Engert,Marc André,Massimo Federico,Timothy M Illidge,Martin Hutchings,Marco Ladetto +6 more
TL;DR: The aim of this work is to provide a systematic review and meta-analysis of the literature on canine coronavirus infection and its role in mortality and morbidity and to help clarify the role of immune checkpoints in this disease.
References
More filters
Journal ArticleDOI
A Prognostic Score for Advanced Hodgkin's Disease
Dirk Hasenclever,Volker Diehl +1 more
TL;DR: The prognostic score developed may be useful in designing clinical trials for the treatment of advanced Hodgkin's disease and in making individual therapeutic decisions, but a distinct group of patients at very high risk could not be identified on the basis of routinely documented demographic and clinical characteristics.
Journal ArticleDOI
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
Andrea Gallamini,Martin Hutchings,Luigi Rigacci,Lena Specht,Francesco Merli,Mads Hansen,Caterina Patti,Annika Loft,Francesco Di Raimondo,Francesco d'Amore,Alberto Biggi,Umberto Vitolo,Caterina Stelitano,R Sancetta,Livio Trentin,Stefano Luminari,Emilio Iannitto,Simonetta Viviani,Ivana Pierri,Alessandro Levis +19 more
TL;DR: PET-2 overshadows the prognostic value of IPS and emerges as the single most important tool for planning of risk-adapted treatment in advanced HL.
Journal ArticleDOI
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease
Volker Diehl,Jeremy Franklin,Michael Pfreundschuh,B. Lathan,Ursula Paulus,Dirk Hasenclever,Hans Tesch,Richard Herrmann,Bernd Dörken,Hans Konrad Müller-Hermelink,Eckhardt Dühmke,Markus Loeffler +11 more
TL;DR: Investigation of three combinations of chemotherapy for advanced Hodgkin's disease found increased-dose BEACOPP resulted in better tumor control and overall survival than did COPP-ABVD and standard BEACopP.
Journal ArticleDOI
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Martin Hutchings,Annika Loft,Annika Loft,Mads Hansen,Mads Hansen,Lars Møller Pedersen,Lars Møller Pedersen,Thora Buhl,Thora Buhl,Jesper Jurlander,Jesper Jurlander,Simon Buus,Simon Buus,Susanne Keiding,Susanne Keiding,Francesco d'Amore,Francesco d'Amore,Anne-Marie Boesen,Anne-Marie Boesen,Anne Kiil Berthelsen,Anne Kiil Berthelsen,Lena Specht,Lena Specht +22 more
TL;DR: For prediction of PFS, interim FDG-PET was as accurate after two cycles as later during treatment and superior to computerized tomography (CT) at all times and in regression analyses, early interimFDG- PET was stronger than established prognostic factors.
Journal ArticleDOI
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
Andreas Engert,Volker Diehl,Jeremy Franklin,Andreas Lohri,Bernd Dörken,Wolf-Dieter Ludwig,Peter Koch,Mathias Hänel,Michael Pfreundschuh,Martin Wilhelm,Lorenz Trümper,Walter-Erich Aulitzky,Martin Bentz,Mathias J. Rummel,Orhan Sezer,Hans Konrad Müller-Hermelink,Dirk Hasenclever,Markus W. Löffler +17 more
TL;DR: The 10-year follow-up of the HD9 trial demonstrates a stabilized significant improvement in long-term FFTF and OS for BEACOPP escalated in advanced-stage HL, and challenges ABVD as standard of care for this patient population.
Related Papers (5)
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
Andreas Engert,Annette Plütschow,Hans Theodor Eich,Andreas Lohri,Bernd Dörken,Peter Borchmann,Bernhard Berger,Richard Greil,Kay C. Willborn,Martin Wilhelm,Jürgen Debus,Michael J. Eble,Martin Sökler,A. D. Ho,Andreas Rank,Arnold Ganser,Lorenz Trümper,Carsten Bokemeyer,Hartmut Kirchner,Jörg Schubert,Zdenek Kral,Michael Fuchs,Hans Konrad Müller-Hermelink,Rolf-Peter Müller,Volker Diehl +24 more
Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group
Andreas Engert,Petra Schiller,Andreas Josting,Richard Herrmann,Peter Koch,M. Sieber,F. Boissevain,Maike de Wit,Jörg Mezger,Eckhart Dühmke,Normann Willich,Rolf-Peter Müller,Bernhard F. Schmidt,Helmut Renner,Hans Konrad Müller-Hermelink,Beate Pfistner,Jürgen Wolf,Dirk Hasenclever,Markus W. Löffler,Volker Diehl +19 more
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
Andreas Engert,Heinz Haverkamp,Carsten Kobe,Jana Markova,Christoph Renner,A. D. Ho,Josée M. Zijlstra,Zdenek Kral,Michael Fuchs,Michael Hallek,Lothar Kanz,Hartmut Döhner,Bernd Dörken,Nicole Engel,Max S. Topp,Susanne Klutmann,Holger Amthauer,Andreas Bockisch,Regine Kluge,Clemens Kratochwil,Otmar Schober,Richard Greil,Reinhard Andreesen,Michael Kneba,Michael Pfreundschuh,Harald Stein,Hans Theodor Eich,Rolf-Peter Müller,Markus Dietlein,Peter Borchmann,Volker Diehl +30 more